newsfilter
← Latest News
GlobeNewswire·

Tectonic Therapeutic Announces Third Quarter 2026 Financial Results and Recent Business Highlights

Reported favorable safety, tolerability and pharmacokinetic ("PK") results from the single ascending-dose portion of the TX2100 Phase 1a clinical trial in healthy adult volunteers; FDA granted TX2100 Fast Track